F. Yalcinkaya et al., LOW-DOSE ERYTHROPOIETIN IS EFFECTIVE AND SAFE IN CHILDREN ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, Pediatric nephrology, 11(3), 1997, pp. 350-352
Hypertension is one of the most important complications of erythropoie
tin (rHuEPO) therapy in dialysis patients. In this study, the effect o
f two different dosage regiments of subcutaneous rHuEPO on blood press
ure [BP] was evaluated in 20 anemic children on continuous ambulatory
peritoneal dialysis (CAPD). Patients were randomized to receive rHuEPO
50 U/kg, either once a week (group 1, 50 U/kg per week) or three time
s a week (group 2, 150 U/kg per week). At the beginning of the study,
8 patients in group 1 and 8 patients in group 2 were on antihypertensi
ve therapy. In group 1, the hematocrit increased gradually and signifi
cantly from 18.98% +/- 1.79% to 30.1% +/- 1.62% after 6 months, while
in group 2 it rapidly increased from 19.53% +/- 1.86% to 32.4% +/- 1.1
1% after 3 months. A significant increase in the mean arterial BP was
observed in group 2. Antihypertensive therapy had to be increased in a
ll of the 8 previously hypertensive patients and had to be initiated i
n 1 of the 2 originally normotensive patients in the same group. None
of the patients in group 1 required a change in antihypertensive medic
ation. We conclude that during treatment with rHuEPO preexisting hyper
tension and the dose of rHuEPO are the most important risk factors for
the development or worsening of hypertension in children on CAPD, and
gradual elevation of hematocrit by low-dose rHuEPO avoids the develop
ment of severe hypertension.